APA (7th ed.) Citation

Piemonti, L., Keymeulen, B., Gillard, P., Linn, T., Bosi, E., Rose, L., . . . Allegretti, M. (2022). Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial. Diabetes, obesity & metabolism, 24(9), 1840-1849. https://doi.org/10.1111/dom.14770

Chicago Style (17th ed.) Citation

Piemonti, Lorenzo, et al. "Ladarixin, an Inhibitor of the Interleukin‐8 Receptors CXCR1 and CXCR2, in New‐onset Type 1 Diabetes: A Multicentre, Randomized, Double‐blind, Placebo‐controlled Trial." Diabetes, Obesity & Metabolism 24, no. 9 (2022): 1840-1849. https://doi.org/10.1111/dom.14770.

MLA (9th ed.) Citation

Piemonti, Lorenzo, et al. "Ladarixin, an Inhibitor of the Interleukin‐8 Receptors CXCR1 and CXCR2, in New‐onset Type 1 Diabetes: A Multicentre, Randomized, Double‐blind, Placebo‐controlled Trial." Diabetes, Obesity & Metabolism, vol. 24, no. 9, 2022, pp. 1840-1849, https://doi.org/10.1111/dom.14770.